[go: up one dir, main page]

AR133890A1 - INHIBITION OF HUMAN α₅β₁ INTEGRIN - Google Patents

INHIBITION OF HUMAN α₅β₁ INTEGRIN

Info

Publication number
AR133890A1
AR133890A1 ARP240102531A ARP240102531A AR133890A1 AR 133890 A1 AR133890 A1 AR 133890A1 AR P240102531 A ARP240102531 A AR P240102531A AR P240102531 A ARP240102531 A AR P240102531A AR 133890 A1 AR133890 A1 AR 133890A1
Authority
AR
Argentina
Prior art keywords
inhibition
formula
integrin
human
compound
Prior art date
Application number
ARP240102531A
Other languages
Spanish (es)
Inventor
James E Dowling
Kerim Babaoglu
Alex Buckmelter
Matthew Bursavich
Bryce Harrison
Fu Lin
- Lippa Blaise Yang
Thomas Andrew Mteague
Prolay Mondal
Meghan Monroy
Qi Qiao
Dawn Troast
Cheng Zhong
Katherine Chong
Emilie Flood
Aleksey Gerasyuto
Eugene Hickey
Evelyne Houang
Mats Svensson
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of AR133890A1 publication Critical patent/AR133890A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para tratar o prevenir una enfermedad o afección que responde a la inhibición de la integrina a₅b₁ humana mediante la administración de un compuesto de fórmula (1) a un paciente que lo necesite. Mediante la administración del compuesto de fórmula (1) se pueden tratar numerosas enfermedades y afecciones. Un compuesto caracterizado porque responde a la fórmula (1), o una sal farmacéuticamente aceptable del mismo.Methods for treating or preventing a disease or condition that responds to the inhibition of human integrin α₅β₁ by administering a compound of formula (1) to a patient in need. Numerous diseases and conditions can be treated by administering the compound of formula (1). A compound characterized in that it responds to formula (1), or a pharmaceutically acceptable salt thereof.

ARP240102531A 2020-08-26 2024-09-20 INHIBITION OF HUMAN α₅β₁ INTEGRIN AR133890A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063687186P 2020-08-26 2020-08-26
US202363584383P 2023-09-21 2023-09-21

Publications (1)

Publication Number Publication Date
AR133890A1 true AR133890A1 (en) 2025-11-12

Family

ID=97832793

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102531A AR133890A1 (en) 2020-08-26 2024-09-20 INHIBITION OF HUMAN α₅β₁ INTEGRIN

Country Status (1)

Country Link
AR (1) AR133890A1 (en)

Similar Documents

Publication Publication Date Title
CL2022002592A1 (en) Use of agents for treatment of respiratory conditions
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
MX370361B (en) Pharmaceutical preparation including pyridylamino acetic acid compound.
CL2021003312A1 (en) Composition comprising pridopidine and an analog thereof for the treatment of huntington's disease and its symptoms.
CO2024012872A2 (en) Treatment of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) in pediatric patients with mirdametinib
MX2020006284A (en) Bis-choline tetrathiomolybdate for treating wilson disease.
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
CL2022000781A1 (en) Medicinal cognitive treatments
CL2022003039A1 (en) il4i1 inhibitors and methods of use.
AR119159A1 (en) ANGIOEDEMA TREATMENTS
DOP2023000060A (en) LINE-1 INHIBITORS TO TREAT DISEASES BACKGROUND OF THE INVENTION
MX2019005104A (en) Zinc-y-pga compositions and methods for treating cancer.
EA202090242A1 (en) TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS
AR114306A1 (en) TREATMENT AND PREVENTION OF SLEEP DISORDERS
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
CL2021003303A1 (en) Treatment for synucleinopathies.
AR133890A1 (en) INHIBITION OF HUMAN α₅β₁ INTEGRIN
CR20230472A (en) Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
MX2008002456A (en) Use of ambroxol for the treatment of rhinovirus infections.
UY39593A (en) TREATMENT FOR MALIGNANT SOLID TUMORS
BR112022000734A2 (en) Method for treating cancer in a patient, use of compound 1, and, compound 1
MX2019003720A (en) COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S EVIL AND PARKINSON'S DISEASE.
BR112018072164A2 (en) pharmaceutical composition, method for treating and / or preventing a patient's skin disease and / or alleviating the symptoms thereof, and cosmetic use of a composition